Morse, Elizabeth

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature

Protein Degradation and InhibitorsChromatin Remodeling and Cancer

Cited by 4,262

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 767

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

Bradner, J. E., Mak, R., Tanguturi, S. K., Mazitschek, R., Haggarty, S. J., Ross, K., Chang, C. Y., Bosco, J., West, N., Morse, E., et al. (2010) · Proceedings of the National Academy of Sciences

Hemoglobinopathies and Related DisordersHistone Deacetylase Inhibitors Research

Cited by 211